Trials / Completed
CompletedNCT00647777
Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg
Single-Dose Food In Vivo Bioequivalence Study of Olanzapine Tablets (5 mg; Mylan) and Zyprexa® Tablets (5 mg; Eli Lilly) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Mylan Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to investigate the bioequivalence of Mylan olanzapine 5 mg tablets to Eli Lilly's Zyprexa® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administered under fed conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olanzapine Tablets 5 mg | 5mg, single dose fed |
| DRUG | Zyprexa® Tablets 5 mg | 5mg, single dose fed |
Timeline
- Start date
- 2003-06-01
- Primary completion
- 2003-07-01
- Completion
- 2003-07-01
- First posted
- 2008-04-01
- Last updated
- 2024-04-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00647777. Inclusion in this directory is not an endorsement.